Celgene’s Otezla Shines, On Track To Be A Fourth Blockbuster Pillar

Sales of the psoriasis drug increased 170% in the second quarter to $242m, giving the blood cancer specialist a strong anchor as it looks to expand in inflammation and immunology.

Celgene Corp.’s psoriasis drug Otezla (apremilast) is expected to become a blockbuster seller this year, surpassing sales of $1bn, management said during the company’s second quarter sales and earnings call July 28. The drug would become the company’s fourth blockbuster franchise and the first outside of Celgene’s specialty in oncology.

Otezla generated sales of $242m in the quarter, a 170% increase over the second quarter a year ago. The oral...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.